Purple Biotech (PPBT)
Purple Biotech reported revenue of 1M USD for the year ending 31 December 2020, up 0.0% from 1M a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in USD.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
2020 · ending 31 December 2020 |
1M |
+0.0% |
| Operating Income |
2025 · ending 31 December 2025 |
27.5M |
+149.5% |
| Net Income |
2025 · ending 31 December 2025 |
-26.5M |
— |
| Operating Cash Flow |
2025 · ending 31 December 2025 |
-5.7M |
— |
| Free Cash Flow |
2025 · ending 31 December 2025 |
-5.7M |
— |
| Shares Outstanding |
2025 · ending 31 December 2025 |
480.1K |
-70.7% |
| EPS |
2025 · ending 31 December 2025 |
0.03 |
-99.5% |
Revenue and profit by financial year
As filed, in USD. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2020 | 2020-12-31 |
1M | 13.2M | 28.1M | 1.5M |
|---|
| 2019 | 2019-12-31 |
1M | 6.7M | 5.4M | -2M |
|---|
| 2018 | 2018-12-31 |
1M | 8.8M | 5.6M | -8.5M |
|---|
| 2017 | 2017-12-31 |
100K | 12.1M | 12.9M | -8.6M |
|---|
Every period
Revenue Annual
| Period | Ending | Revenue |
|---|
| FY20 | 2020-12-31 | 1M |
|---|
| FY19 | 2019-12-31 | 1M |
|---|
| FY18 | 2018-12-31 | 1M |
|---|
| FY17 | 2017-12-31 | 100K |
|---|
Operating Income Annual
| Period | Ending | Operating Income |
|---|
| FY25 | 2025-12-31 | 27.5M |
|---|
| FY24 | 2024-12-31 | 11M |
|---|
| FY23 | 2023-12-31 | 22.3M |
|---|
| FY22 | 2022-12-31 | 22.6M |
|---|
| FY21 | 2021-12-31 | 17.9M |
|---|
Net Income Annual
| Period | Ending | Net Income |
|---|
| FY25 | 2025-12-31 | -26.5M |
|---|
| FY24 | 2024-12-31 | -7.3M |
|---|
| FY23 | 2023-12-31 | -20M |
|---|
| FY22 | 2022-12-31 | -21.8M |
|---|
| FY21 | 2021-12-31 | 18.5M |
|---|
Operating Cash Flow Annual
| Period | Ending | Operating Cash Flow |
|---|
| FY25 | 2025-12-31 | -5.7M |
|---|
| FY24 | 2024-12-31 | -14.4M |
|---|
| FY23 | 2023-12-31 | -19.9M |
|---|
| FY22 | 2022-12-31 | -16.7M |
|---|
| FY21 | 2021-12-31 | -374K |
|---|
Free Cash Flow Annual
Operating cash flow minus capital expenditure.
| Period | Ending | Free Cash Flow |
|---|
| FY25 | 2025-12-31 | -5.7M |
|---|
| FY23 | 2023-12-31 | -19.9M |
|---|
| FY22 | 2022-12-31 | -16.8M |
|---|
| FY21 | 2021-12-31 | -489K |
|---|
| FY20 | 2020-12-31 | 1.5M |
|---|
Shares Outstanding Annual
Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.
| Period | Ending | Shares Outstanding |
|---|
| FY25 | 2025-12-31 | 480.1K |
|---|
| FY24 | 2024-12-31 | 1.6M |
|---|
| FY23 | 2023-12-31 | 1.1M |
|---|
| FY22 | 2022-12-31 | 904.1K |
|---|
| FY21 | 2021-12-31 | 17.6M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 0.03 |
|---|
| FY24 | 2024-12-31 | 4.99 |
|---|
| FY23 | 2023-12-31 | 17.96 |
|---|
| FY22 | 2022-12-31 | 23.97 |
|---|